Class information for:
Level 1: AROMATASE INHIBITORS//EXEMESTANE//ANASTROZOLE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1155 2718 40.8 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
232 19686 TAMOXIFEN//AROMATASE INHIBITORS//ANASTROZOLE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 AROMATASE INHIBITORS Author keyword 452 46% 27% 731
2 EXEMESTANE Author keyword 251 74% 7% 184
3 ANASTROZOLE Author keyword 251 63% 9% 250
4 LETROZOLE Author keyword 120 40% 9% 235
5 FULVESTRANT Author keyword 107 58% 5% 124
6 ENDOCRINE THERAPY Author keyword 83 34% 8% 204
7 TAMOXIFEN Author keyword 44 10% 15% 416
8 ADJUVANT ENDOCRINE THERAPY Author keyword 42 69% 1% 36
9 OVARIAN ABLATION Author keyword 31 71% 1% 25
10 EDINBURGH BREAST UNIT Address 21 34% 2% 51

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 AROMATASE INHIBITORS 452 46% 27% 731 Search AROMATASE+INHIBITORS Search AROMATASE+INHIBITORS
2 EXEMESTANE 251 74% 7% 184 Search EXEMESTANE Search EXEMESTANE
3 ANASTROZOLE 251 63% 9% 250 Search ANASTROZOLE Search ANASTROZOLE
4 LETROZOLE 120 40% 9% 235 Search LETROZOLE Search LETROZOLE
5 FULVESTRANT 107 58% 5% 124 Search FULVESTRANT Search FULVESTRANT
6 ENDOCRINE THERAPY 83 34% 8% 204 Search ENDOCRINE+THERAPY Search ENDOCRINE+THERAPY
7 TAMOXIFEN 44 10% 15% 416 Search TAMOXIFEN Search TAMOXIFEN
8 ADJUVANT ENDOCRINE THERAPY 42 69% 1% 36 Search ADJUVANT+ENDOCRINE+THERAPY Search ADJUVANT+ENDOCRINE+THERAPY
9 OVARIAN ABLATION 31 71% 1% 25 Search OVARIAN+ABLATION Search OVARIAN+ABLATION
10 ENDOCRINE RESISTANCE 20 37% 2% 44 Search ENDOCRINE+RESISTANCE Search ENDOCRINE+RESISTANCE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANASTROZOLE 501 61% 20% 531
2 LETROZOLE 302 49% 16% 448
3 FIRST LINE THERAPY 264 58% 11% 305
4 AROMATASE INHIBITORS 193 30% 20% 537
5 EXEMESTANE 162 65% 6% 155
6 CONTINUED TAMOXIFEN 159 96% 2% 49
7 TAMOXIFEN THERAPY 158 42% 11% 287
8 COMBINATION TRIAL 140 79% 3% 90
9 ENDOCRINE THERAPY 118 25% 15% 407
10 MEGESTROL ACETATE 105 29% 11% 309

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review 2012 66 73 74%
Drug therapy: Aromatase inhibitors in breast cancer 2003 371 89 62%
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis 2011 95 26 58%
Mechanisms of Endocrine Resistance in Breast Cancer 2011 183 81 32%
Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer 2015 2 93 56%
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved 2013 24 157 55%
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings 2014 7 70 69%
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence 2015 1 51 75%
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline 2015 1 95 74%
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women 2009 45 84 79%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EDINBURGH BREAST UNIT 21 34% 1.9% 51
2 HLTH SCI IL 1 15 71% 0.4% 12
3 BREAST GRP 7 46% 0.4% 12
4 SENOL EASTERN SWITZERLAND 7 48% 0.4% 11
5 GYNECOL ENDOCRINOL ONCOL 6 71% 0.2% 5
6 EDINBURGH BREAKTHROUGH BREAST UNIT 6 100% 0.1% 4
7 FRENCH BREAST CANC GRP 6 100% 0.1% 4
8 INT BREAST CANC STUDY GRP STAT 5 60% 0.2% 6
9 IBCSG STAT 5 31% 0.5% 14
10 AUSTRALIAN NEW ZEALAND BREAST CANC TRIALS GRP 5 34% 0.4% 12

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000189436 ESTROGENIC RECRUITMENT//AMINOGLUTETHIMIDE//CYCLIC TREATMENT
2 0.0000154644 ENDOXIFEN//DESMETHYLTAMOXIFEN//N DESMETHYL TAMOXIFEN
3 0.0000141073 ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS
4 0.0000128381 19 OXYGENATION//HUMAN PLACENTAL MICROSOME//HUMAN PLACENTAL MICROSOMES
5 0.0000117572 TAMOXIFEN//TOREMIFENE//DROLOXIFENE
6 0.0000112385 STEROID SULFATASE//ESTRONE SULFATASE//AROMATASE
7 0.0000104352 RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX//BAZEDOXIFENE
8 0.0000096409 ESTROGEN RECEPTOR VARIANTS//JC HEUSON CANCEROL MAMMAIRE//SERV HISTOL CYTOL EXPT
9 0.0000073296 ONCOTYPE DX//TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE
10 0.0000066966 CRLC OSCAR LAMBRET//UKRAINIAN ONCOL RADIOL//6 METHYL 1 3 8 TRICHLORODIBENZOFURAN